TRIM33 and dermatomyositis: Autoantibodies targeting the E3 ubiquitin-ligase family member transcriptional intermediary factor 1γ (TIF1γ), are associated with a significantly increased risk of cancer-associated myositis (CAM) in adults [1], with malignancy rates of 38–80% reported in anti-TIF1γ positive adult dermatomyositis (DM) patients [2].